Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7187MR)

This product GTTS-WQ7187MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7187MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15302MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ10280MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LFG 316
GTTS-WQ9172MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ8578MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ9415MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ10114MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ1124MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ1443MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACC-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW